Strategic Ownership Brainfarma operates under controlled ownership by Hypera S.A., with a large manufacturing footprint in Anápolis-GO and substantial intercompany sales to the parent. Sales opportunities can focus on cross-sell of Hypera portfolio brands, enlisting Brainfarma as a regional production and distribution partner for existing products or new lines.

Gen/Estab Portfolio The company holds registrations for traditional, generic and similar medicines including Doralgina, Gastrol, Histamin and Massageol. This suggests opportunities to expand in-over-the-counter and generic segments by leveraging Brainfarma’s established regulatory and manufacturing capabilities to introduce or scale additional products.

Regional Scale With one of the largest manufacturing facilities in Latin America and substantial production for the parent Hypera, Brainfarma demonstrates capacity to absorb higher-volume contracts. Sales opportunities include contract manufacturing, white-labeling, and toll manufacturing for new or existing Hypera brands or external clients seeking scale.

Financial Footprint Revenue in the 25 to 50 million USD range indicates a mid-market profile with room for growth through expanded product lines, increased contract manufacturing, and targeted regional business development within Brazil and nearby markets where Hypera and Brainfarma already operate.

Growth Fit As a Brazilian pharmaceutical manufacturing partner with a strong portfolio and proximity to Hypera’s distribution network, Brainfarma presents a compelling entry point for strategic sourcing, co-development, and supply-chain collaborations aimed at accelerating product launches and expanding reach in the generics and OTC space.